The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
EJHP Highlights: Telaprevir and Boceprevir for treatment of Hepatitis C
Ahead of the WHO’s World Hepatitis Day, EAHP’s EU Monitor highlights a recent EJHP article by Mark Nolan on the use of antiviral protease inhibitors Telaprevir and Boceprevir for the treatment of Hepatitis C.
The article discus
ses some of the special points about both medicines, including patient counselling around such issues as adverse reactions, drug interactions and medication storage.
Full article available here